Bayer (BAYRY) issued a “surprisingly positive” report for its experimental blood thinner over the weekend, pushing Bristol Myers Squibb (BMY) stock higher on Monday. Both companies are testing drugs that block the activated form of Factor XI, a protease involved in blood coagulation. By blocking Factor XIa, the companies hope to stop bleeding. On Sunday, Bayer said a combination using…
